Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?
Christopher Hourigan • 14 Jun 2019
Impact of conditioning intensity of allo-SCT for AML with molecular residual disease
GAIA/CLL13: venetoclax-based combination treatments vs standard chemoimmunotherapy in frontline CLL
Barbara Eichhorst • 16 Dec 2021